 RADNOR, Pa., Sept. 27, 2021 PRNewswire -- NRx Pharmaceuticals Nasdaq: NRXP, a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMITM. 